NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) — FMW Media Inc.’s New to The Street is happy to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical firm targeted on creating and commercializing merchandise to deal with uncommon ailments the place there may be an unmet medical want, will seem on its syndicated TV retailers, together with Newsmax, Fox Business Network and Bloomberg, as a sponsored program.
Dr. Christopher J. Schaber, Chairman, President, and CEO of Soligenix will seem on the present with TV Host Jane King to evaluation the Company’s strong pipeline and upcoming This fall 2022 milestones which have the potential to be transformational for Soligenix.
Soligenix has two distinctive business segments: Specialized BioTherapeutics and Public Health Solutions. The Company’s Specialized BioTherapeutics section focuses on creating merchandise for orphan ailments and areas of unmet medical want in oncology and irritation. The Public Health Solutions section develops warmth steady vaccines and therapeutics for navy and civilian functions in ricin publicity, rising and antibiotic-resistant infectious illness, and viral illness, together with Ebola, Marburg, and COVID-19.
“With several near-term and potentially transformational catalysts, most importantly the submission of our new drug application (NDA) for HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer, we are pleased to feature Soligenix in a series of interviews hosted by New to the Street that will air on national television. These interviews provide an avenue to inform the investment community about our important Q4 2022 milestones,” acknowledged Dr. Schaber. “Building on the successful Phase 3 clinical trial of HyBryte™ in the treatment of CTCL, we will now look to file the NDA before year end with the US Food and Drug Administration. In addition, we will be expanding on synthetic hypericin’s clear biologic activity, and will be initiating a Phase 2 study in December in mild-to-moderate psoriasis, where we’ve previously demonstrated preliminary efficacy in a Phase 1/2 proof of concept trial in this disease indication.”
Soligenix, Inc. has a pipeline of spectacular biopharmaceutical merchandise, a powerful stability sheet, and an skilled and devoted administration group contributing to its ongoing successes.
Vince Caruso, CEO of FMW Media Corp. and the Creator / Producer of New to The Street TV, acknowledged, “We look forward to sharing Soligenix and its story with our televised audiences. Our syndicated televised platform is a perfect fit for Soligenix to further its media reach about the Company’s business activities, and its exciting pipeline of products, especially HyBryte™.”
The filmed broadcastings of New to The Street’s interviews with Soligenix on Newsmax TV, the Fox Business Network, and Bloomberg TV, as a sponsored program, will probably be aired at instances to be introduced within the close to future.
About Soligenix, Inc.
Soligenix, Inc. (Nasdaq: SNGX) is a late-stage biopharmaceutical firm targeted on creating and commercializing merchandise to deal with uncommon ailments the place there may be an unmet medical want. The Specialized BioTherapeutics business section is creating and transferring towards the potential commercialization of HyBryte™ (SGX301 or artificial hypericin) as a novel photodynamic remedy using secure, seen gentle to deal with cutaneous T-cell lymphoma (CTCL). With a profitable Phase 3 research accomplished, regulatory approval is being sought and commercialization actions for this product candidate are being superior initially within the US Development packages on this business section additionally embrace the growth of artificial hypericin (SGX302) into psoriasis, our first-in-class innate protection regulator (IDR) expertise, dusquetide (SGX942) for the remedy of inflammatory ailments, together with oral mucositis in head and neck most cancers, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/remedy of gastrointestinal (GI) problems characterised by extreme irritation together with pediatric Crohn’s illness (SGX203).
The Company’s Public Health Solutions business section contains lively growth packages for RiVax®, its ricin toxin vaccine candidate, and SGX943, its therapeutic candidate for antibiotic-resistant and rising infectious illness, and its vaccine packages concentrating on filoviruses (similar to Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (brought on by SARS-CoV-2). The Company’s vaccine growth packages incorporate its proprietary warmth stabilization platform expertise, referred to as ThermoVax®. To date, this business section has had authorities grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). For additional data relating to Soligenix, Inc., please go to the Company’s web site at https://www.soligenix.com and comply with them on LinkedIn and Twitter at @Soligenix_Inc .
About FMW Media
FMW Media operates one of many longest-running U.S. and International sponsored and Syndicated Nielsen Rated programming tv manufacturers, “New to The Street,” and its blockchain present, “Exploring The Block.” Since 2009, these manufacturers have run biographical interview section exhibits throughout main U.S. tv networks. The paid-for-television programming platforms can probably attain over 540 million properties within the U.S. and worldwide markets. FMW’s New to The Street / Newsmax televised broadcasting platform airs its syndication on Sundays at 10 -11 AM ET. FMW can be one of many nation’s largest consumers of linear tv, lengthy and short-form paid programming – https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements Disclaimer:
This press launch incorporates forward-looking statements inside Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some circumstances, you’ll be able to establish forward-looking statements by the next phrases: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the destructive of those phrases or different comparable terminology. However, not all forward-looking statements include these phrases. Forward-looking statements usually are not a assure of future efficiency or outcomes and won’t essentially be correct indications of the instances at which such efficiency or outcomes are achieved. This press launch needs to be thought-about in all filings of the Companies contained within the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contacts:
Bryan Johnson
+1 (631) 766-7462
[email protected]
“New to The Street” Business Development Office
1-516-696-5900
[email protected]
